Scientists Find Body's Natural 'Off Switch' That Stops Chronic Inflammation
New research reveals how fat-derived molecules naturally shut down inflammation, offering hope for safer arthritis and heart disease treatments.
Summary
University College London researchers have discovered how the body naturally turns off inflammation through fat-derived molecules called epoxy-oxylipins. These molecules control immune cells that drive chronic diseases like arthritis and heart disease. In a human study, participants received harmless bacteria injections to trigger inflammation, then were given a drug that boosts these protective molecules. Those who received the treatment experienced faster pain relief and had significantly fewer harmful inflammatory cells in their blood and tissues. The drug works by blocking an enzyme that normally breaks down these beneficial molecules, allowing them to better control the immune response. This discovery could lead to safer treatments for millions suffering from chronic inflammatory conditions, as it works with the body's natural healing processes rather than simply suppressing the entire immune system like current medications.
Detailed Summary
Scientists at University College London have identified the body's natural mechanism for shutting down inflammation, a discovery that could revolutionize treatment for chronic diseases affecting millions worldwide. This breakthrough addresses a critical gap in understanding how our immune system transitions from active defense to healing.
The research focused on epoxy-oxylipins, small fat-derived molecules that act as natural immune regulators. These molecules prevent the accumulation of intermediate monocytes, specific immune cells linked to chronic inflammation and tissue damage in conditions like arthritis, heart disease, and diabetes.
Researchers conducted a controlled human study with 48 healthy volunteers who received injections of harmless UV-killed bacteria to trigger temporary inflammation. Half received GSK2256294, a drug that blocks the enzyme normally breaking down protective epoxy-oxylipins, while others received placebo. The treatment was tested both preventively and therapeutically.
Participants receiving the drug experienced faster pain resolution and significantly reduced levels of harmful inflammatory cells in blood and tissue. The medication worked by boosting levels of protective molecules, particularly 12,13-EpOME, which suppresses the p38 MAPK protein pathway driving immune cell transformation.
This discovery represents a paradigm shift from current anti-inflammatory treatments that broadly suppress immune function. Instead, this approach works with the body's natural resolution mechanisms, potentially offering safer alternatives for treating chronic inflammatory diseases. The research suggests that enhancing our innate ability to turn off inflammation could provide more targeted, effective treatments with fewer side effects than existing therapies that simply block inflammatory processes.
Key Findings
- Fat-derived epoxy-oxylipins naturally regulate immune response and prevent chronic inflammation
- Blocking enzyme sEH increases protective molecules, reducing harmful immune cells by significant margins
- Treatment accelerated pain resolution in human volunteers within hours of administration
- Specific molecule 12,13-EpOME suppresses p38 MAPK pathway driving inflammatory cell transformation
- Both preventive and therapeutic approaches showed effectiveness in controlled human trials
Methodology
This is a news report summarizing peer-reviewed research published in Nature Communications. University College London provides high research credibility. Evidence based on controlled human trials with 48 volunteers using standardized inflammatory triggers and validated biomarkers.
Study Limitations
Study conducted in healthy volunteers with artificially induced inflammation may not fully represent chronic disease states. Long-term safety and efficacy of sEH inhibition requires further investigation. Translation to clinical treatments will require additional trials and regulatory approval.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.